Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review

Executive Summary

House and Senate letters ask why Mylan's autoinjector doesn't have competition, offering a preview of potential debates on renewal of the generic user fee program.


Related Content

Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers
Why Generic EpiPen Is Not The Answer – Until FDA Says It Is
FDA's Combo Products Review Transformation Begins
PDUFA First: Fees To Support Device Center Staff
FDA To Update Quality Metrics Guidance
Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact
For Generics Industry, Will Larger Firms Mean Weaker Lobbying?
Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL
Cheap Drugs Create Quality Temptations, FDA Official Says
Copaxone Generics: FDA Approval Standards Defy Teva’s Argument On Complexity


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts